Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cardiff Oncology, Inc. | a15-9730_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 23, 2015
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35558 |
|
27-2004382 |
|
(State or other jurisdiction |
|
(Commission File |
|
IRS Employer |
|
of incorporation or organization) |
|
Number) |
|
Identification No.) |
11055 Flintkote Avenue, Suite A
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 23, 2015, Trovagene, Inc. (the “Company”) issued a press release , announcing that study investigator, John Cuzick, Ph.D., will present clinical results from the PREDICTORS 4 study featuring the Company’s urine-based HPV assay and its ability to determine high risk HPV types in women using non-invasive urine samples. The study results will be presented during the Keynote Lecture for the Preventive Research Session at the National Cervical Cancer Consortium and Symposium of HPV Vaccine and Cervical Cancer Prevention’s 13th Annual Meeting in Beijing. Dr. Cuzick, director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London, will present the study results at 1:30 p.m. CST on April 25. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
|
99.1 |
|
Press Release of Trovagene, Inc. dated April 23, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 23, 2015
|
|
TROVAGENE, INC. | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Antonius Schuh |
|
|
|
Antonius Schuh |
|
|
|
Chief Executive Officer |